VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ATRC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ATRCAtriCure, Inc.
$58.54$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksATRCCash Flow

AtriCure, Inc. (ATRC) Cash Flow Statement

22Y historyFree accessUpdated daily

Free cash flow margin improved to 15.5% in Q3 2026 with FCF of $23.9M, but a $21.5M working capital outflow in Q1 2026 and quarterly SBC near $12.5M suggest cash conversion remains uneven.

Income StatementBalance SheetCash FlowRatios

ATRC Cash Flow Statement

Annual statement

ATRC Cash Flow Statement

AtriCure, Inc. (ATRC) cash flow statement — 22-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04
Cash from Operations68.55M57.33M12.2M4.48M-22.14M-13.78M-19.87M-15.81M-4.17M-8.94M-15.12M-7.84M-21.6M-5.22M-1.94M-1.99M-33.43K419.95K-5.71M-8.12M-12.47M-7.62M-3.8M
Operating CF Margin %-10.73%2.62%1.12%-6.7%-5.02%-9.62%-6.85%-2.07%-5.12%-9.75%-6.04%-20.1%-6.38%-2.76%-3.08%-0.06%0.77%-10.33%-16.8%-32.6%-24.6%-19.84%
Operating CF Growth %323.08%369.8%172.17%120.25%-60.67%30.65%-25.67%-279.07%53.37%40.84%-92.8%63.69%-313.63%-169.73%2.54%-5841.34%-107.96%107.35%29.64%34.9%-63.68%-100.41%-
Net Income14.88M-11.45M-44.7M-30.44M-46.47M50.2M-48.16M-35.19M-21.14M-26.89M-33.34M-27.21M-16.21M-11.46M-7.53M-5.46M-3.79M-16.49M-10.17M-11.25M-13.72M-12.68M-9.45M
Depreciation & Amortization21.16M20.53M18.73M14.81M11.71M10.44M9.55M9.37M8.75M9.13M9.3M6.28M4.77M2.02M1.9M1.92M2.36M2.77M2.68M2.32M1.89M1.55M962.36K
Stock-Based Compensation47.32M44.69M40.41M35.73M28.77M28.08M22.64M17.98M16.5M14.62M11.7M9M7.57M3.08M3.47M2.94M2.77M3.89M2.67M0000
Deferred Taxes0000084.78M1.51M445K724K21K1.11M1.43M1.13M29K53K5.42M259.77K-59K-57K0000
Other Non-Cash Items7.78M7.85M16.12M2.62M2.72M-182.43M1.22M-3.79M-10.41M-3.81M1.19M61K-7.82M115K100K-5.3M-15.64K10.82M342.64K1.85M1.11M3.31M4.94M
Working Capital Changes-22.61M-4.29M-18.36M-18.24M-18.88M-4.85M-6.64M-4.62M1.4M-2M-5.08M2.6M-11.04M996K78K-1.51M-1.62M-507.25K-1.18M-1.04M-1.74M204.36K-246.49K
Change in Receivables-13.75M-5.61M-8.3M-9.87M-8.99M-10.09M5.09M-3.2M-2.84M-1.46M-1.98M-900K-4.17M-1.25M-417K-198.95K-2.3M-685.99K609.34K0000
Change in Inventory-8.63M-2.26M-7.74M-21.83M-7.3M-4.27M-5.26M-5.15M-146K-4.48M-79K-2.95M-4.34M-2.29M865K-923.51K-850.15K1.5M-1.15M-1.38M-1.25M-193.56K-448.41K
Change in Payables4.62M-960K-1.53M6.18M2.68M4.71M-1.56M2.79M-2.4M1.29M-1.07M4.01M-944K1.45M-132K787.5K893.28K-1.55M597.46K0000
Cash from Investing-21.11M-14.55M30.23M21.82M44.01M23.5M-156.2M-2.15M-85.4M3.76M-12.08M-10.5M-30.62M-14.15M-2.8M2.72M-3.33M-2.17M-1.17M-8.79M114.64K-14.74M-1.51M
Capital Expenditures-15.61M-9.05M-11.46M-12M-16.88M-9.75M-5.26M-12.18M-6.21M-6.38M-7.69M-24M-9.21M-2.86M-2.98M-1.52M-1.81M-1.36M-1.75M-3.04M-1.68M-1.95M-1.51M
CapEx % of Revenue2.65%1.69%2.46%3.01%5.11%3.56%2.55%5.28%3.08%3.65%4.96%18.49%8.57%3.5%4.25%2.36%3.07%2.49%3.16%6.3%4.39%6.3%7.9%
Acquisitions-5.5M000-44.01M-33.26M0-17.24M6K03K-7.58M03.71M0002K-417.29K-3.34M0-6.42M0
Investments-----------------------
Other Investing0-5.5M41.69M-30M44.01M33.26M800K39K6K10.14M3K-10.55M77K48K24K389.48K5.24K6M-6M020K00
Cash from Financing-7.92M1.18M-3.6M-32K-7.06M-7.64M189.39M14.37M100.18M2.76M27.7M13.96M65.87M26.83M2.66M4.85M-1.44M-914.01K5.28M15.03M-277.37K44.61M89.18K
Debt Issued (Net)-974K5.05M-1.67M-992K-899K-816K-667K19.87M15.63M-1.69M24.56M77K-6.38M-2.06M1.9M3.37M-2.3M-1.23M4.94M-393.68K-369.83K1.4M0
Equity Issued (Net)-4.93M-3.87M-6.95M-6.56M-12.2M-18.01M175.93M-9.03M78.42M-2.01M-1.7M-782K65.5M26.47M-401K1.47M0281.04K103.64K15.42M92.47K43.22M89.18K
Dividends Paid00000000000000000000000
Share Repurchases-12.53M-11.16M-6.95M-6.56M-12.2M-18.01M-13.03M-9.03M-4.46M-2.01M-1.7M-782K-331K-398K-401K-783K0000000
Other Financing-2.01M05.02M7.52M6.04M11.19M14.13M3.54M6.13M6.46M4.83M14.67M6.75M2.41M1.16M0852.05K33.34K239.87K0000
Net Change in Cash39.17M44.71M38.41M26.21M14.45M1.71M13.46M-3.75M10.42M-2.4M444K-4.62M13.49M7.14M-2.01M5.53M-4.67M-2.54M-1.55M-1.89M-12.54M22.26M-5.22M
Free Cash Flow57.94M48.28M-11.26M-37.51M-39.02M-23.53M-25.13M-27.99M-10.38M-15.33M-22.81M-31.84M-30.81M-8.09M-4.92M-3.51M-1.85M-940.51K-7.46M-11.16M-14.15M-9.57M-5.31M
FCF Margin %9.82%9.03%-2.42%-9.4%-11.81%-8.58%-12.17%-12.13%-5.15%-8.77%-14.71%-24.54%-28.67%-9.87%-7.01%-5.45%-3.13%-1.72%-13.5%-23.1%-36.99%-30.91%-27.74%
FCF Growth %262.06%529%70%3.86%-65.82%6.35%10.23%-169.63%32.27%32.8%28.36%-3.35%-280.99%-64.32%-40.25%-89.94%-96.41%87.39%33.18%21.11%-47.86%-80.07%-
FCF per Share1.161.01-0.24-0.81-0.85-0.51-0.60-0.74-0.30-0.47-0.72-1.13-1.17-0.40-0.30-0.22-0.12-0.06-0.53-0.83-1.17-1.59-2.91
FCF Conversion (FCF/Net Income)3.89x-5.01x-0.27x-0.15x0.48x-0.27x0.41x0.45x0.20x0.33x0.45x0.29x1.33x0.46x0.26x0.36x0.01x-0.03x0.56x0.72x0.91x0.60x0.40x
Interest Paid-3.92M5.25M5.95M6.38M4.27M4.22M4.37M3.72M3.87M2M1.51M232K115K473K607K405K418K460.93K127.66K0000
Taxes Paid-1.63M1.29M619K395K192K190K217K259K65K37K30K20K146K30K14K30K30K17.3K14K0000

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetHealthy
Cash FlowImproving
Top Statement Risk

Working capital and SBC dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Flow Diverges From Net Income

According to recent SEC filings, AtriCure's operating cash flow of $30.3M in Q3 2026 against net income of $4.1M produces an OCF-to-net-income ratio of 7.46, a gap driven largely by $12.5M of stock-based compensation and $5.5M of D&A that are non-cash add-backs.

The conversion ratio is inflated by non-cash add-backs, so the more meaningful signal is that operating cash flow has turned positive on a sustained basis while GAAP earnings remain close to breakeven. The Q1 2026 print, with operating cash flow of negative $4.0M against near-zero net income, suggests working capital timing rather than a deterioration in underlying earnings quality. Investors should monitor whether operating cash flow stays positive once stock-based compensation is treated as a real economic cost.

Free Cash Flow Turns Consistently Positive

Based on reported figures, AtriCure's free cash flow margin improved from negative 10.7 percent in Q1 2025 to 15.5 percent in Q3 2026, with FCF of $23.9M in the latest quarter following a negative Q1 2026 print of $7.8M.

The move to sustained positive free cash flow across the second half of 2025 and Q2 to Q3 2026 suggests the business has reached a self-funding threshold on a quarterly basis. The Q1 2026 negative FCF, driven by a $21.5M working capital outflow, indicates the trend remains lumpy rather than linear. Investors should weigh the recent run of positive quarters against this timing-driven volatility before extrapolating the trend.

Light Capital Intensity Supports Cash Generation

As reported in financial statements, AtriCure's capital expenditures ran between 1.1 and 3.1 percent of revenue across the last ten quarters, with $6.4M spent in Q3 2026 representing 4.1 percent of revenue.

Low capital intensity is consistent with a disposable-device model in which manufacturing is not capital heavy, which helps explain how free cash flow can turn positive despite modest operating margins. Capex runs at roughly the level of quarterly D&A of about $5 million, suggesting spending is not materially below maintenance levels. The supplied data do not separate maintenance from growth capex, so the true reinvestment requirement remains unclear.

Working Capital Drives Quarterly Swings

According to recent SEC filings, AtriCure's working capital change was a $21.5M outflow in Q1 2026 and a $19.6M outflow in Q1 2025, versus a $12.3M inflow in Q3 2024, indicating a recurring first-quarter pattern.

The recurrence of large first-quarter working capital outflows suggests a seasonal pattern in receivables, inventory build, or payables timing rather than a one-off event. Given the single-use product line and sensitivity to stocking orders, inventory and receivable timing may account for much of this swing. Investors should monitor whether these outflows reverse within the year, since persistent build would raise questions about collections efficiency.

Cumulative Cash Generation Still Lags Accounting Profit

Based on reported figures, AtriCure's cumulative operating cash flow across the ten quarters shown is positive but modest relative to stock-based compensation of roughly $11 to $12 million per quarter, which exceeds net income in most periods.

Over the observed window, stock-based compensation has consumed a substantial share of operating cash generation on an economic basis, even though it is non-cash on the statement. Net income has been negative or near zero for most of the period, meaning the cash profile is currently stronger than the earnings profile. Investors should treat the improving free cash flow as partly dependent on equity-based pay that dilutes shareholders.

Cash Strength May Mask Equity Cost

Based on reported figures, AtriCure's quarterly SBC of roughly $11 to $12 million exceeds net income in most recent periods, so the improving free cash flow may overstate economic cash generation if equity compensation is treated as a real cost.

Adding back stock-based compensation is standard, but it means shareholders are funding a meaningful portion of talent costs through dilution rather than cash. If SBC were treated as a cash expense, the trailing free cash flow profile would look materially weaker than the headline figures suggest. This analysis is inferential and based only on the supplied quarterly data, so the degree of dilution and any future cash-settled obligations warrant further investigation.

ATRC — Frequently Asked Questions

Quick answers to the most common questions about buying ATRC stock.

How much cash does AtriCure, Inc. (ATRC) generate from operations?

AtriCure, Inc. (ATRC) generated $57.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is AtriCure, Inc.'s free cash flow?

AtriCure, Inc. (ATRC) generated $48.3M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is AtriCure, Inc.'s capital expenditure (CapEx)?

AtriCure, Inc. (ATRC) spent $9.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does AtriCure, Inc. distribute cash to shareholders?

In 2025, AtriCure, Inc. (ATRC) spent $11.2M on share repurchases. This shows the company's commitment to returning capital to its equity investors.